search
Back to results

A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Placebo
50 mg SP2086
100 mg SP2086
200 mg SP2086
100 mg Sitagliptin
Sponsored by
Jiangsu HengRui Medicine Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring Sp2086, Phase II, monotherapy

Eligibility Criteria

20 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 20 Years to 70 Years ,Male and Female diagnosed with type 2 diabetes mellitus
  • Patients not on an oral antihyperglycemic agent (OHA) with 7.0% ≤HbA1C ≤10.5%,or not on an OHA for 3 months with 7.0% ≤HbA1C ≤10.5%
  • BMI 19~35 kg/m2

Exclusion Criteria:

  • Patient has history of type 1 diabetes mellitus
  • Patient has history of ketoacidosis
  • Patient has history of severe unconscious hypoglycemosis
  • Patient has history of acute and chronic pancreatitis or pancreatic injury that may lead to high risk of pancreatitis
  • Patient has history of decompensated heart failure (NYHA class III and IV), unstable angina, stroke or transient ischemic attack, myocardial infarction, persistence and clinical
  • Patient has history of a history of hypertension, and after antihypertensive treatment, systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg
  • Patient has severe liver or kidney disease,alanine aminotransferase >2×UNL, Aspartate Aminotransferase >2×upper normal limit(UNL);total bilirubin >2×UNL; creatinine>1.5 mg/dL (Male,132.6μmol/L) ,>1.4 mg/dL(Female,123.8μmol/L)
  • Patient has severe chronic gastrointestinal disease or therapy that may affect drug absorption, such as gastrointestinal surgery
  • Patient has severe haematological diseases or other diseases leading to hemolyze and red blood cell unstable (malaria、haemolytic anaemia eg. )
  • Patient has other endocrine diseases, for example hyperthyroidism、hypothyroidism、hypercortisolism、multiple endocrine neoplasia and so on
  • Patient has history of malignancy
  • Patient has history of alcohol or drug abuse

Sites / Locations

  • Chinese PLA General Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Placebo Comparator

Experimental

Experimental

Experimental

Active Comparator

Arm Label

Placebo

50 mg SP2086

100 mg SP2086

200 mg SP2086

100 mg Sitagliptin

Arm Description

Outcomes

Primary Outcome Measures

the change from baseline in HbA1c at 12 week

Secondary Outcome Measures

Percentage of Participants Achieving Less Than (<) 6.5% or <7% HbA1c Levels
Change From Baseline in Fasting Plasma Glucose at Week 4, 8 and 12
Post-meal total and incremental glucose,insulin and C-peptide area under the curve at week 4 ,12
Change from baseline in Homeostasis model assessment-beta(HOMA-β) at week 4,week12
Change From Baseline in lipid at Week 4, 8 and 12
Change From Baseline in Body Weight at Week 4,8,12

Full Information

First Posted
October 17, 2013
Last Updated
October 21, 2013
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT01969357
Brief Title
A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes
Official Title
A Multicenter Randomized, Double-blind, Placebo and Positive Controlled ,Parallel Group ,Phase II Study to Access the Efficacy and Safety of SP2086 Treated Type 2 Diabetes Patients
Study Type
Interventional

2. Study Status

Record Verification Date
October 2013
Overall Recruitment Status
Completed
Study Start Date
June 2011 (undefined)
Primary Completion Date
April 2012 (Actual)
Study Completion Date
June 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Jiangsu HengRui Medicine Co., Ltd.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
SP2086 is a new dipeptidy1 peptidase(DPP)-4 inhibitors. This study aims to explore the effective dose range of SP2086 in Patients with type 2 diabetes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Sp2086, Phase II, monotherapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
200 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Title
50 mg SP2086
Arm Type
Experimental
Arm Title
100 mg SP2086
Arm Type
Experimental
Arm Title
200 mg SP2086
Arm Type
Experimental
Arm Title
100 mg Sitagliptin
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Tablets(n=4),once daily for 84 days
Intervention Type
Drug
Intervention Name(s)
50 mg SP2086
Intervention Description
Tablets(n=1),50mg strength+tablets(n=3) 0 mg once daily for 84 days
Intervention Type
Drug
Intervention Name(s)
100 mg SP2086
Intervention Description
Tablets(n=1),100 mg strength+tablets(n=3) once 0 mg daily for 84 days
Intervention Type
Drug
Intervention Name(s)
200 mg SP2086
Intervention Description
Tablets(n=2),100 mg strength+tablets(n=2) 0mg once daily for 84 days
Intervention Type
Drug
Intervention Name(s)
100 mg Sitagliptin
Intervention Description
Tablets(n=1),100 mg strength+tablets(n=3),0 mg strength once daily for 84 days
Primary Outcome Measure Information:
Title
the change from baseline in HbA1c at 12 week
Time Frame
baseline, week 12
Secondary Outcome Measure Information:
Title
Percentage of Participants Achieving Less Than (<) 6.5% or <7% HbA1c Levels
Time Frame
week 12
Title
Change From Baseline in Fasting Plasma Glucose at Week 4, 8 and 12
Time Frame
Baseline, Week 4, 8, 12
Title
Post-meal total and incremental glucose,insulin and C-peptide area under the curve at week 4 ,12
Time Frame
baseline, week 4 ,12
Title
Change from baseline in Homeostasis model assessment-beta(HOMA-β) at week 4,week12
Time Frame
baseline, week 4,12week
Title
Change From Baseline in lipid at Week 4, 8 and 12
Time Frame
baseline, week 4, 8, 12
Title
Change From Baseline in Body Weight at Week 4,8,12
Time Frame
baseline, Week 4, 8,12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 20 Years to 70 Years ,Male and Female diagnosed with type 2 diabetes mellitus Patients not on an oral antihyperglycemic agent (OHA) with 7.0% ≤HbA1C ≤10.5%,or not on an OHA for 3 months with 7.0% ≤HbA1C ≤10.5% BMI 19~35 kg/m2 Exclusion Criteria: Patient has history of type 1 diabetes mellitus Patient has history of ketoacidosis Patient has history of severe unconscious hypoglycemosis Patient has history of acute and chronic pancreatitis or pancreatic injury that may lead to high risk of pancreatitis Patient has history of decompensated heart failure (NYHA class III and IV), unstable angina, stroke or transient ischemic attack, myocardial infarction, persistence and clinical Patient has history of a history of hypertension, and after antihypertensive treatment, systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg Patient has severe liver or kidney disease,alanine aminotransferase >2×UNL, Aspartate Aminotransferase >2×upper normal limit(UNL);total bilirubin >2×UNL; creatinine>1.5 mg/dL (Male,132.6μmol/L) ,>1.4 mg/dL(Female,123.8μmol/L) Patient has severe chronic gastrointestinal disease or therapy that may affect drug absorption, such as gastrointestinal surgery Patient has severe haematological diseases or other diseases leading to hemolyze and red blood cell unstable (malaria、haemolytic anaemia eg. ) Patient has other endocrine diseases, for example hyperthyroidism、hypothyroidism、hypercortisolism、multiple endocrine neoplasia and so on Patient has history of malignancy Patient has history of alcohol or drug abuse
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Changyu Pan, M.D.
Organizational Affiliation
Chinese PLA General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chinese PLA General Hospital
City
Beijing
Country
China

12. IPD Sharing Statement

Learn more about this trial

A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes

We'll reach out to this number within 24 hrs